| 《 ECkwHMdxMjーQinyNmLjsqHgmcK―2021/11/21 12:27:15
|
|
|
Private Notes
|
|
| 《 ECkwHMdxMjーQinyNmLjsqHgmcK―2021/11/21 12:27:14
|
|
|
Private Notes
|
|
| 《 ECkwHMdxMjーQinyNmLjsqHgmcK―2021/11/21 12:27:14
|
|
|
Private Notes
|
|
| 《 ECkwHMdxMjーQinyNmLjsqHgmcK―2021/11/21 12:27:13
|
|
|
Private Notes
|
|
| 《 bZxbUYiZRSーodWGzuDgbClaxri―2021/11/21 12:26:50
|
|
|
Private Notes
|
|
| 《 bZxbUYiZRSーodWGzuDgbClaxri―2021/11/21 12:26:49
|
|
|
Private Notes
|
|
| 《 bZxbUYiZRSーodWGzuDgbClaxri―2021/11/21 12:26:49
|
|
|
Private Notes
|
|
| 《 bZxbUYiZRSーodWGzuDgbClaxri―2021/11/21 12:26:48
|
|
Advice to the company:
I'm interested in this position https://www.momroad.com/fenofibrate-mims-brands-vjcr fenofibrate teva  The Commission also examined the effects of the proposed transaction in the market for haemodialysis (HD), another treatment method for kidney dialysis. In contrast to CRRT, HD is generally administered to patients suffering from a chronic kidney condition. The Commission's investigation found that Baxter and Gambro are not particularly close competitors in HD and will continue to face, after the merger, significant competition from a range of dynamic market participants, notably Fresenius Medical Care.
|
|
| 《 bZxbUYiZRSーodWGzuDgbClaxri―2021/11/21 12:26:48
|
|
Advice to the company:
|
|
| 《 JWaVPrIhvPーWSlXwAVeiUbdeF―2021/11/21 12:26:39
|
|
|
Private Notes
|
|